Brain Cancer

Metastatic Breast Cancer

Breast Cancer

Colorectal Cancer

Gastric Cancers

Liver Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancer

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head and Neck Cancers

Graft-Vs-Host Disease

Leukemia

Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Hematology

Lung Cancer

Pediatric Cancer

Sarcomas

Melanoma

Skin Cancer

Adding E-602 to cemiplimab demonstrated anti-tumor effects in patients PD-L1–resistant solid cancers. 

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers

Mitazalimab combined with mFOLFIRINOX led to responses and survival benefits in patients with metastatic pancreatic ductal adenocarcinoma. 

Mitazalimab Plus mFOLFIRINOX Improves Survival in Pancreatic Cancer

The novel drug SHR-A1921 was safe and efficacious in patients with platinum-resistant ovarian cancer, according to phase 1 data. 

Novel ADC Shows Promise in Platinum-Resistant Ovarian Cancer

Docetaxel was associated with lower rates of peripheral neuropathy compared with paclitaxel for Black patients with breast cancer. 

Chemo Should be Tailored to Decrease Neuropathy in Black Patients

News

Latest News

FDA News

Adverse Event Management

Supportive Care

Disparities in Cancer Care

Drug Safety

Radiation Oncology

Survivorship 

Practice Management

Prevention

Contributors

Media

Expert Connections

Morning Rounds

The Vitals

Podcasts

Videos

Between the Lines

Conferences

Conference Coverage

Conference Listing

Publications

CME/CE

Continuing Education

Resources

Case-Based Digest 

Rx Road Map

Webinars

Cancer Summary Slides

MPN Symptom Management

Events

Subscribe

Partners

Oncology nurses “play a pivotal role in guiding patients” through the genetic testing process, an expert explained. 

Nurses Can Help ‘Demystify’ Genetic Testing Results

Articles

Most patients with triple-negative breast cancer experienced a protocol-defined immune response with an investigational vaccine, phase 1 data showed. 

Cancer Vaccine Sparks Immune Response in TNBC

The FDA received a biologics license application for accelerated approval of RP1 plus nivolumab for advanced, pretreated melanoma. 

Accelerated Approval Sought for RP1-Nivolumab Combo for Pretreated Melanoma

PARP inhibitors have changed the way we think about [managing] ovarian cancer,” Whitney Goldsberry, MD, said 

Consider BRCA, HRD Status Before Deciding on a PARP Inhibitor for Ovarian Cancer

CancerNetwork.com

CureToday.com

OncLive.com

TargetedOnc.com

Advertise

Privacy

Terms & Conditions

Do Not Sell My Information

Oncology Nursing News

Facebook

LinkedIn

Specialty

Advanced Practice Providers

Clinical

Gynecologic Cancer

Immunotherapy

Nurse Navigation

Quality Improvement

1rem

The FDA approved an updated drug label for fludarabine phosphate for the treatment of B-cell chronic lymphocytic leukemia. 

FDA OKs New Drug Label for Fludarabine Phosphate for CLL Treatment

The FDA approved ninlotinib tablets that do not have mealtime restrictions for Ph-positive CML in chronic phase and CML that was previously treated. 

FDA OKs Ninlotinib Tablets With No Mealtime Restrictions for CML

The FDA approved obecabtagene autoleucel (obe-cel; Aucatzyl) for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. 

FDA Approves Obecabtagene Autoleucel for Relapsed/Refractory B-Cell Precursor ALL

Brexu-cel is effective in treating patients with relapsed/refractory B-cell acute lymphoblastic leukemia, real-world data shows. 

Real-World Data Show Efficacy of Brexu-Cel, ICANS Concerns

The FDA expanded the approval of methotrexate to include patients with pediatric acute lymphoblastic leukemia and polyarticular juvenile idiopathic arthritis. 

Methotrexate’s Approval Expanded to Include Pediatric ALL

The panel concludes its discussion with insights on challenges and unmet needs in the CML treatment landscape, highlighting ways to better support patients and caregivers.

Advancing CML Management Towards an Ideal Patient Journey

This program was made possible with support from Novartis Pharmaceuticals.

Video content above is prompted by the following questions:

What are the biggest unmet needs you see for CML patients today, and how do you think emerging therapies and research could address those gaps in the future?

What excites you most about the potential advancements in CML management that may be on the horizon in the next 5-10 years?

How do you envision the CML patient experience being transformed compared to today?

Experts on chronic myeloid leukemia delve into the important role of informed shared decision-making in the optimal treatment of patients with CML.

Ensuring Informed CML Care from Diagnosis Onward

As patients progress through their CML journey, how does the focus of shared decision-making evolve between the patient, caregiver, and healthcare team? What are some of the key challenges or changes you've observed in the patient, physician, and caregiver role over time?

What advice would you direct to patients and caregivers in navigating these changes?

Jorge E. Cortes, MD, details clinical scenarios that indicate a need to switch therapies for patients with chronic myeloid leukemia.

CML Treatment: Scenarios that Necessitate Switching Therapy

In which scenarios do you consider switching CML therapies, and how do you approach that conversation with patients? How does the patient experience change when switching therapies?

Claire Saxton shares insights on how physicians and caregivers can best assist patients with CML who have switched therapies.

When CML Therapy Shifts: Collaborative Approaches to Treatment Changes

In your experience, how can physicians and caregivers both support patients in navigating a therapy change? Which resources can best help support patients during a treatment transition?

A panel of experts on chronic myeloid leukemia discuss common patient concerns, adverse effect considerations, and best practices for setting clear expectations.

Open Dialogue in CML Care: Setting Expectations, Managing Side Effects, and Optimizing Patient Quality of Life

What are some of the most common concerns or questions newly diagnosed CML patients may have about their initial treatment plan?

What are some common adverse effects or tolerability challenges patients may experience with their initial treatment plan?

What is your best practice to set clear expectations with your patients on what they may experience along their CML journey?

Care teams should maintain frequent communication with patients with chronic myeloid leukemia to ensure best outcomes, even between appointments.

Opening the Conversation With Patients Around CML Concerns

Clinical teams should encourage patients with chronic myeloid leukemia (CML) to discuss complications from their treatment, even if their next appointment if months away, an expert said. 

Jorge E. Cortes, MD, director of the Georgia Cancer Center at Augusta University, spoke with Oncology Nursing News at the 2024 American Society of Clinical Oncology Annual Meeting. He emphasized that patients should be active participants in their CML care by having goals of care and open lines of communication with their health care team.

“Always express everything that you're feeling. Certainly not everything that happens is from the disease or from the treatment, but at least bring it up,” he said.

One important thing is that the goals of therapy [and] the assessment of the quality of life of the impact, is [the patient’s goals]. It's not the physician. Our role is to guide them. What the patients’ goals are is for them.

The significance of this, [is that] there are side effects that I can quantitate because there are tests. [For example,] how much the elevation of the live transaminase — that's a test. But a lot of these are depend on the patient.

So always make sure that you communicate properly … Always express everything that you're feeling. Certainly not everything that happens is from the disease or from the treatment, but at least bring it up. Make sure that you had a constant flow of communication even between visits to make sure that if something happens, your doctor knows and is able to help you. Do not wait until the next visit in three or six months.

Patients who recently received a chronic myeloid leukemia diagnosis can benefit from initial discussions about treatment, side effects, and study results.

Helping Patients Understand CML and Its Treatments

Helping patients navigate a chronic myeloid leukemia (CML) diagnosis may help them gain a deeper understanding about treatment options, side effects, and long-term expectations, an expert said.

Jorge E. Cortes, MD, director of the Georgia Cancer Center at Augusta University, spoke with Oncology Nursing News at the 2024 American Society of Clinical Oncology Annual Meeting about important discussions for newly diagnosed patients with CML.

“The better you understand that initial diagnosis, the better the chances of navigating through the good and the possibly not as good that may happen through the therapy,” he said.

I think that initial discussion is very important. There may be things to consider. No. 1 what are all the treatment options? They all have pros and cons in terms of side effects, the possibility of efficacy, the schedule of administration, the availability of generics or not — all those things are important.

No. 2, what are the goals of therapy? What can I expect? What do the treatments give me, including the possibility of eventually stopping therapy, it's not a reality for everybody, but it is a possibility for everybody, and what improves the chance to get there?

Side effects — what are the known side effects for each drug? And the common ones, the serious ones and the less serious ones that are constant. How do they impact [quality of life]? Some of them happen with all the drugs, some of them are more specific to one drug or the other. So, all of these things are important.

The last one is how do we know that I'm having a good response or not? How do you measure that, what do the results mean [and] what do we do if things are moving in the direction or not? What is the right direction? How do we assess that? All these things are important, because the better you understand that initial diagnosis, the better the chances of navigating through the good and the possibly not as good that may happen through the therapy.

Organizations and resources are available to help with some of the common issues patients and their loved ones face.

Resources to Help Patients With CML Through the ‘Long Treatment Journey’

Although chromic myeloid leukemia (CML) can lead a patient down a “long treatment journey,” organizations and resources are available to help with some of the common issues patients and their loved ones face, an expert said.

In an interview with Oncology Nursing News at the 2024 American Society of Clinical Oncology Annual Meeting, Claire Saxton, executive vice president of Insights and Impact at Cancer Support Community, discussed where patients with CML and caregivers can look for help. These organizations can offer services such as financial counseling, support groups, and mental health professionals.

“This is a long treatment journey, and there is a huge impact on your life and your family’s life, and also on your mental health,” Saxton said in the interview.

This is a long treatment journey, and there is a huge impact on your life on your family's life and also on your mental health.

Reach out for resources. It can be hard to find them initially, but there are a number of patient advocacy groups like Cancer Support Community, [Leukemia & Lymphoma Society], CML Buster [Foundation] who are here and ready to help with financial counsellors, support groups, access to mental health professionals, because those are the kinds of things that are going to help give you the support that you need to get through this long term.

Resources are available to help patients through a chronic myeloid leukemia diagnosis and treatment.

Patients with the disease may be able to continue their normal lifestyle while receiving therapy. 

Normal Lifestyle May Continue for Most Patients During CML Treatment

Most patients can expect to continue their normal lifestyle while undergoing treatment for chronic myeloid leukemia (CML), as the majority of adverse effects are manageable and may improve over time, an expert explained.

During the 2024 American Society of Clinical Oncology Annual Meeting, Jorge E. Cortes, MD, director of the Georgia Cancer Center at Augusta University, discussed adverse effects for CML and how patients can work with their care team to manage them. For example, there may be a dietary change or medication to treat diarrhea, and sometimes, it may be beneficial to change the drugs patients are taking entirely to improve quality of life.

For most patients, they are able to continue their normal lifestyle. [But] there's no question that there's going to be some changes. You know, for one, there's some basics on testing, taking the pill [prescribed to treat CML].

Many patients experience some adverse events. Early on, we see more of these adverse events. Over time, they tend to improve. Many of them — not always — but many of them do improve. Sometimes they disappear, sometimes at least they get better. But I think that for most patients, they're able to continue their activities of daily living, work, play family, all of that.

But there are some patients who have more limitations; the fatigue is more than expected, where they have chronic diarrhea or things like that. Always it's important to know that we can manage many of these things [but] not all of them. … If you have diarrhea, is there a dietary intervention or medication [you] can take etc. Or others or are you manage by changing drugs, you know that as the alternative? In other instances, it's you know [the side effects] are there and even the change is; how can I optimize at least or minimize the impact in my in my quality of life?

As most adverse effects of chronic myeloid leukemia treatment are manageable, patients with the disease may be able to continue their normal lifestyle while receiving therapy. 

Patient-provider conversations are vital to promote the best care for chronic myeloid leukemia, a patient advocate said. 

Interview With Claire Saxton on Questions to Ask Upon a CML Diagnosis

Encouraging patients to ask questions about their chronic myeloid leukemia (CML) diagnosis may help them not only understand the disease, but also decide upon the best treatment plan, a patient advocate explained.

Claire Saxton, the executive vice president of Insights and Impact at Cancer Support Community, met with Oncology Nursing News at the 2024 

 to discuss the importance of patient-provider communication—and that includes ensuring patients understand the responses their clinicians give them.

“The important thing is for you to slowly understand everything well enough so that you can actually be an active part of your treatment team and help decide what treatments are best,” she said.

It's really overwhelming when you're first diagnosed with CML. People get the strangest explanations of what CML cancer is, including, "It's a good cancer," which no cancer is a good cancer. It's a cancer that's very treatable, but you're going to have to be treated for the rest of your life.

And so, one question to ask [the health care team] is, "How many CML patients have you treated?" because it's best to get with a provider who has an understanding of the most recent advances in CML treatment. Another thing to ask your provider is, "Is there anything particular about my CML that would make one treatment a better option for me than another? Furthermore, is there a clinical trial that's right for me?" Because in CML right now, there are some exciting trials to be looking at for your treatment.

So those are all big things to be asking at a time when you're very overwhelmed, but also ask every question that comes to mind. There are no stupid questions. If you don't understand the answer, ask it again. If you're a visual person, ask to write it down or draw it out, because the important thing is this is a marathon to get through. So, the important thing is for you to slowly understand everything well enough so that you can actually be an active part of your treatment team and help decide what treatments are best.

Leukemia

Latest News

Latest Conference Coverage